Nedlands
Nedlands
Nedlands, Washington, Australia9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC) | neoplasm | Active, not recruiting | Not applicable | 2026-07-29 | NCT05667766 | |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, brainstem cancer, central nervous system cancer, central nervous system disorder, diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27M-mutant, epithelial neoplasm, glioma, grade III glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-06-26 | NCT05009992 | |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, T-cell leukemia, T-cell non-Hodgkin lymphoma, enteropathy-associated T-cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, hydroa vacciniforme-like lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monomorphic epitheliotropic intestinal T-cell lymphoma, neoplasm, primary cutaneous gamma-delta t-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-06-17 | NCT05475925 | |
| First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 / Phase 2 | 2026-06-05 | NCT06554795 | |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03900429 | |
| Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC) | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Inflammation, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, gonadal disorder, neoplasm, ovarian disorder, primary ovarian failure, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Not stated | 2026-04-14 | NCT07527819 | |
| The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 1 / Phase 2 | 2026-03-27 | NCT05756322 | |
| Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | Cancer of Urinary Tract, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Non-Muscle Invasive Bladder Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urinary system neoplasm, urothelial carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-12 | NCT05544552 | |
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis | inclusion body myositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease | Active, not recruiting | Phase 2 / Phase 3 | 2025-07-28 | NCT06450886 |